Showing 51-60 of 9109 results for "".
- ASDS Awards Inagural Research Grant Recipient of Fredric S. Brandt, MD, Innovations in Aesthetics Fellowshiphttps://practicaldermatology.com/news/asds-awards-inagural-research-grant-recipient-of-fredric-s-brandt-md-innovations-in-aesthetics-fellowship/2458790/Abigail Waldman, MD, of Chicago, has been chosen as the inaugural research grant recipient of the Fredric S. Brandt, MD, Innovations in Aesthetics Fellowship Fund. Dr. Waldman was awarded $41,500 for her research project entitled “Patient Motivations and Preferences Regarding the Decision to Seek …
- Coming Soon to a City Near You: Sciton Inc.'s Bright Lights Big City BBL 2018 Tourhttps://practicaldermatology.com/news/coming-soon-to-a-city-near-you-sciton-incs-bright-lights-big-city-bbl-2018-tour/2457815/Sciton. Inc.’s Bright Lights Big City BroadBand Light (BBL) 2018 Tour is now in its third year. The 2018 Tour, featuring San Francisco dermatologist Patrick Bitter Jr., MD, kicks off in early June in Fort Lauderdale, followed by Chicago, New York City and Austin, before making a last stop in Washi…
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Administration has cleared the company's investigat…
- Exploring OX40’s Role in AD: A Conversation With Dr. Stephan Weidingerhttps://practicaldermatology.com/news/exploring-ox40s-role-in-ad-a-conversation-with-dr-stephan-weidinger/2462078/The anti-Ox40-ligand antibody amlitelimab performed well in the phase 2b Stream-AD trial of adults with moderate-to-severe atopic dermatitis, according to research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin. Amlitelimab demonstrated clinically m…
- Provectus Biopharmaceuticals, Inc.'s Common Shares Begin Trading on NYSEhttps://practicaldermatology.com/news/20140516-provectus_biopharmaceuticals_incs_common_shares_begin_trading_on_nyse/2459239/Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that its shares will begin trading on the NYSE MKT today, Friday, May 16, 2014. The company's ticker symbol will remain “PVCT” but it will withdra…
- AD Pipeline Watch: Apogee Therapeutics, Inc.’s IL-13 Blocker Enters Phase 1 Trialhttps://practicaldermatology.com/news/ad-pipeline-watch-apogee-therapeutics-incs-il-13-blocker-enters-phase-1-trial/2461911/The first volunteers have been dosed in a Phase 1 trial for Apogee Therapeutics, Inc.’s APG777 for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. APG777 is a novel, subcutaneous extended half-life monoclonal antibody targeting IL-13. In head-to-head preclinical studies…
- FDA Clears DeepX Diagnostics Inc.'s DermoSight for Telederm Screening of Suspicious Lesionshttps://practicaldermatology.com/news/fda-clears-deepx-diagnostics-incs-dermosight-for-telederm-screening-of-suspicious-lesions/2461763/The US Food and Drug Administration (FDA) has cleared DeepX Diagnostics Inc.’s digital dermatoscope DermoSight for teledermatology screening of suspected skin cancer lesions. DermoSight is currently cleared to acquire skin lesion images for teledermatology assessment, like existing digital dermat…
- Kubota Vision, LEO Pharma A/S to Screen Novel VAP-1 Inhibitors for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/kubota-vision-leo-pharma-as-to-screen-novel-vap-1-inhibitors-for-inflammatory-skin-diseases/2460351/Kubota Vision Inc. signed an Open Innovation Agreement with LEO Pharma A/S to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop novel therapeuti…
- Data Demonstrate Efficacy of ON Light Sciences, Inc.'s DeScribe Transparent PFD Patchhttps://practicaldermatology.com/news/data-demonstrate-efficacy-of-on-light-sciences-incs-describe-transparent-pfd-patch/2458839/Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. “It is estimated that close to 25% of the US population has some sort of t…
- Chicago Dermatologist Dr. Amy S. Paller Wins American Skin Association’s David Martin Carter Mentor Awardhttps://practicaldermatology.com/news/chicago-dermatologist-dr-amy-s-paller-wins-american-skin-associations-david-martin-carter-mentor-award/2460802/Amy S. Paller, MD of the Feinberg School of Medicine at Northwestern University in Chicago received the American Skin Association's David Martin Carter Mentor Award. For more than three decades, ASA's David Martin Carter Mentor Award has honored members of the dermatology community who embody the …